234108-58-8

Basic information

• Product Name: tert-butyl 4-(2-aMinoethyl)-3-oxopiperazine-1-carboxylate
• Synonyms: tert-butyl 4-(2-aMinoethyl)-3-oxopiperazine-1-carboxylate
• CAS NO: 234108-58-8
• Molecular Formula: C₁₁H₂₁N₃O₃
• Molecular Weight: 243.30274
• Mol File: 234108-58-8.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: tert-butyl 4-(2-aMinoethyl)-3-oxopiperazine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-(2-aMinoethyl)-3-oxopiperazine-1-carboxylate(234108-58-8)
• EPA Substance Registry System: tert-butyl 4-(2-aMinoethyl)-3-oxopiperazine-1-carboxylate(234108-58-8)

Safety Data

• Hazardous Substances Data: 234108-58-8(Hazardous Substances Data)

Upstream product

• 76003-29-7 4-(t-butyloxycarbonyl)piperazin-2-one 

Relevant articles and documents

MODULATORS OF G-PROTEIN COUPLED RECEPTORS

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize or partially agonize or antagonize) glucagon?like peptide?1 receptor ("GLP?1R") and/or the gastric inhibitory polypeptide receptor ("GIPR"). The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which modulation (e.g., agonism, partial agonism or antagonism) of GLP?1R and/or GIPR activities is benficial for the treatment or prevention of the underlying pathology and/or symptoms and/or progression of the disease, disorder, or condition. In some embodiments, the modulation results in an enhancment of (e.g., an increase in) existing levels (e.g., normal or below normal levels) of GLP?1R and/or GIPR activity (e.g., signaling). In some embodiments, the chemical entities described herein further modulate (e.g., attenuate, uncouple) -arrestin signaling relative to what is observed with the native ligand. This disclosure also features compositions as well as other methods of using and making the said chemical entities.

SERINE/THREONINE KINASE INHIBITORS

Compounds having the formula I wherein R1, R2, R3, R4, R5, Ra, Rb, Rc, Rd, Re, n, r, s and t are as defined herein and which compounds are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.